Logan Stone Capital’s abrdn Life Sciences Investors HQL Stock Holding History

Logan Stone Capital’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14,778	Closed	-$201K	–	174
2024 Q1	$201K	Sell	14,778 -136,236	-90%	-$1.88M	0.04%	134
2023 Q4	$2.03M	Sell	151,014 -97,602	-39%	-$1.2M	0.41%	65
2023 Q3	$3.1M	Buy	248,616 +169,392	+214%	+$2.23M	0.85%	39
2023 Q2	$1.07M	Sell	79,224 -73,518	-48%	-$1.01M	0.36%	77
2023 Q1	$2.13M	Sell	152,742 -6,081	-4%	-$86.9K	0.84%	38
2022 Q4	$2.26M	Buy	+158,823	New	+$2.3M	0.84%	32

Other funds holding HQL

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

AIA

Absolute Investment Advisers Rosemary Beach, Florida $852M AUM 0.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

1CP

1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return

KIM

Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return

Logan Stone Capital's HQL Position: Q2 2024 in Review

Logan Stone Capital sold out of abrdn Life Sciences Investors (HQL) in Q2 2024, closing a stake of 14,778 shares — an estimated $201K sold.

Logan Stone Capital first reported a position in HQL in Q4 2022 and held it in 6 quarters. The position peaked at $3.1M in Q3 2023. 75 funds tracked by Wall St. Rank hold HQL as of Q2 2024.

Logan Stone Capital reported no remaining abrdn Life Sciences Investors position as of Q2 2024 after selling out during the quarter.
Logan Stone Capital sold 14,778 abrdn Life Sciences Investors shares in Q2 2024, an estimated $201K.
Logan Stone Capital first reported a position in abrdn Life Sciences Investors in Q4 2022 and held it in 6 quarters.
Logan Stone Capital's abrdn Life Sciences Investors position peaked at $3.1M in Q3 2023.
75 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2024.

Based on Logan Stone Capital's 13F filing for Q2 2024, filed 14 Aug 2024.